
# NIH (USA) Initiative on Blood-Based Multi-Cancer Detection (MCD) Tests

David Weinberg MD, MSc Fox Chase Cancer Center Philadelphia, PA, USA October 13, 2023 No relevant conflicts of interest to declare


### Standard Cancer Screening Paradigm

The "ideal" screening test

- Sensitive/specific
- Inexpensive
- Easy to administer
- Can detect the disease early enough to meaningfully intervene
- Few false positives



# Current Recommendations for Cancer Screening in the US



 USPSTF recommends average risk screening for colorectal, cervix, breast and lung (some smokers) cancers

(+) screen → organ specific w/u

- 2. Test characteristics are variable
- 3. Uptake is suboptimal
- 4. Huge disparities in utilization


### The Problem(s) with "One Test-One Cancer"


- Unscreened cancers: 60% of all cancer diagnoses; >70% of cancer deaths
- Aggregate false positive rate of single site screening: 31% (men), 43% (women)
- Annual incidence of OTHER cancers is 2-24x higher than single target sites

# A Better Paradigm?

#### **CURRENT**

- "One organ at a time" detection
- Excludes most cancer types
- Multiple modalities
- Inefficient
- Costly





· Potentially cost-saving

# Liquid Biopsy

Tumor components released into various fluids

Proteins: CEA, survivin, APC, TIMP, osteopontin

Tumor Associated Antigens: CCSA-2,-3,-4, cyclin B, CA 19-9


Cytokines: G-CSF, IL-6, IL-3

Circulating Tumor cells

Hypermethylated genes: Sept 9, FOXE1

mRNA transcripts


microRNA




## Multi-Cancer Early Detection



#### MULTI CANCER EARLY DETECTION MARKET SIZE, 2021 TO 2030 (USD BILLION)



#### One Argument for Multi- Organ Site Screening



Ahlquist, Nature Precision Oncology (2018)

## Theoretical Arguments: For and Against

- There is a 1.3% annual incidence of any cancer in US adults (n=1.2 million).
- Cumulative detection rate using USPSTF tests is about 16% with 10% adherence.
- MCD with 55% sens/99% spec would detect 715 cancers/100,000 screened with a FP rate of 691/100,000. Cumulative PPV = 51%<sup>1</sup>
- MCD + SOC screening adds 0.34 QALYs/person and is cost effective<sup>2</sup>

<sup>1</sup> Liu et al Annals of Oncology 2020
<sup>2</sup> Ortendahk et al Value in Health 2020

## Theoretical Arguments: For and Against

- Cancer screening built on the premise that earlier detection is ALWAYS better than late.
- Increasing awareness of the harms of over diagnosis and over treatment
- 3 "kinds" of cancer:
  - 1. slowly progressive -- early detection benefit (+)
  - 2. rapidly progressive -- early detection benefit (?)
  - 3. indolent -- early detection benefit (-)

At present no way to consistently distinguish among the 3




Figure Model of screening outcomes based on 3 different types of detected lesions. The more detected lesions (increase sensitivity), the more detected indolent lesions (decrease specificity for "true cancers"). IDLE = indolent lesion of epithelial origin.

# Theoretical Arguments: For and Against (2)

Model using SEER data for 40-79y population: Down stage 33% of Stage IV to Stage III ( + similar reductions for Stage III and Stage II...), leads to a **15% reduction** in cancer deaths<sup>1</sup>

Adjusted population, the observed # cancer deaths after 5 years follow up is 285/100,000. The 15% reduction saves 71 lives/100,000.

• Application of a novel MCD with a FP rate of 0.5%, would lead to 500 FP cancer diagnoses for every 71 cancer deaths prevented

# Many Unknowns for MCDs

- Appropriate diagnostic work up(s)
- Follow up of (+) tests without a cancer identified immediately
- Potential harms of FPs, over diagnosis of indolent disease
- Real world use strategies (how often etc.)
- Equitable dissemination strategies across populations

# Vanguard Pilot (NCI): Objectives

- Assess willingness to be randomized to MCED cancer screening versus control.
- Determine adherence to MCED testing and diagnostic follow-up.
- Evaluate the feasibility of defined diagnostic workflows to detect various cancers.
- Determine performance of participating MCED companies to process specimens and return results.
- Identify facilitators and barriers to diverse enrollment in an RCT, especially underserved populations.

# Vanguard Pilot (NCI), n=24,000




Figure 1. Platform study design schema. MCED = multicancer early detection

# Summary

- MCD testing offers a "brave new world"
- In the US, many will want the test
- Demand by patients and industry to move faster than the science
- Vanguard Study will provide key preliminary information

